STEVENSON, Md., Sept. 19, 2016 -- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of Utah on behalf of purchasers of LifeVantage Corporation (Nasdaq:LFVN) (“LifeVantage” or the “Company”) securities during the period between November 4, 2015 and September 13, 2016, inclusive (the “Class Period”). Investors who wish to become proactively involved in the litigation have until November 14, 2016 to seek appointment as lead plaintiff.
If you wish to choose counsel to represent you and the Class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the Class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in LifeVantage securities during the Class Period. Members of the Class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No class has yet been certified in the above action.
The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of the defendants’ failure to disclose during the Class Period that LifeVantage lacked effective internal financial controls, and, as a result, the Company had improperly accounted for sales in certain international markets, along with associated revenue and income tax accruals.
According to the complaint, following a September 13, 2016 press release and Form 8-K announcing a delay in the release of the Company’s fourth quarter and fiscal year 2016 financial results due to sales of the Company’s products in certain international markets and the determination of revenue and the deductibility of commission and incentive expenses associated with such sales, the value of LifeVantage shares declined significantly.
If you have suffered a loss in excess of $100,000 from investment in LifeVantage securities purchased on or after November 4, 2015 and held through the revelation of negative information during and/or at the end of the Class Period and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, without cost or obligation to you, please visit our website at http://www.browerpiven.com/currentsecuritiescases.html. You may also request more information by contacting Brower Piven either by email at [email protected] or by telephone at (410) 415-6616. Brower Piven also encourages anyone with information regarding the Company’s conduct during the period in question to contact the firm, including whistleblowers, former employees, shareholders and others.
Attorneys at Brower Piven have extensive experience in litigating securities and other class action cases and have been advocating for the rights of shareholders since the 1980s. If you choose to retain counsel, you may retain Brower Piven without financial obligation or cost to you, or you may retain other counsel of your choice. You need take no action at this time to be a member of the class.
CONTACT: Charles J. Piven Brower Piven, A Professional Corporation 1925 Old Valley Road Stevenson, Maryland 21153 Telephone: 410-415-6616 [email protected]


Standard Chartered Targets Higher Profitability With Major Workforce Cuts
US-China Trade Talks Sideline Chip Export Controls as Nvidia China Sales Draw Attention
Sonova Beats Profit Forecasts Despite Cochlear Implant Weakness
Samsung Faces Major Strike Threat as Union Restarts Pay Talks
Alphabet Raises Record $3.6 Billion in Yen Bonds to Support AI Expansion
Japan Airlines Signs 10-Year Boeing 787 Maintenance Deal With GE Aerospace
Tencent Shares Jump 4% as AI Models Move Toward Paid Commercial Services
FTC Antitrust Probe Targets Arm Holdings Over Chip Licensing Practices
Elliott Targets Bio-Rad as Shares Continue to Struggle
OpenAI Wins Elon Musk Lawsuit as Jury Rejects Claims Over AI Mission
Standard Chartered Appoints Manus Costello as New CFO Amid Leadership Reshuffle
SpaceX Shareholders Approve 5-for-1 Stock Split Ahead of Potential IPO
TSMC Stake Sale Sends Vanguard Semiconductor Shares Lower
Takeda Hit With $885M Verdict Over Amitiza Generic Drug Delay Scheme
Anthropic to Brief Financial Stability Board on AI-Driven Cyber Risks
Samsung Shares Drop as Labor Union Confirms Planned Strike
TrumpRx Expands Discount Drug Access With 600 Generic Medications 



